login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SANOFI-ADR (SNY) Stock News
USA
- NASDAQ:SNY -
US80105N1054
-
ADR
51.64
USD
+2.12 (+4.28%)
Last: 10/24/2025, 8:00:02 PM
51.08
USD
-0.56 (-1.08%)
After Hours:
10/24/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SNY Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Benzinga
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
2 days ago - By: Investor's Business Daily
- Mentions:
AAPL
Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion
2 days ago - By: Benzinga
- Mentions:
FHB
EAF
NWG
GRC
...
Earnings Scheduled For October 24, 2025
a month ago - By: Stocktwits
- Mentions:
IMRX
Why Immuneering Stock Soared Over 40% After-Hours Today
9 days ago - By: Zacks Investment Research
- Mentions:
AZN
MRK
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
3 days ago - By: Medidata Solutions, Inc.
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
9 days ago - By: Stocktwits
- Mentions:
RVMD
IRON
REGN
LLY
...
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
10 days ago - By: EVOQ Therapeutics, Inc.
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
13 days ago - By: Zacks Investment Research
- Mentions:
TEVA
ALLO
CMMB
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
13 days ago - By: Zacks Investment Research
- Mentions:
REGN
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
15 days ago - By: Zacks Investment Research
- Mentions:
WMT
SNE
C
JBLU
...
Top Research Reports for Walmart, Sony & Citigroup
17 days ago - By: Investor's Business Daily
- Mentions:
APGE
REGN
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
21 days ago - By: The Motley Fool
- Mentions:
NKTR
REGN
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
24 days ago - By: Zacks Investment Research
- Mentions:
TEVA
FOLD
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
25 days ago - By: Zacks Investment Research
- Mentions:
GILD
KYMR
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
26 days ago - By: Stocktwits
- Mentions:
NVAX
Novavax Amends Deal With Sanofi, Broadens Partnership
a month ago - By: Investor's Business Daily
- Mentions:
GSK
AZN
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
a month ago - By: Sanofi
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
a month ago - By: The Motley Fool
- Mentions:
BBAI
MRK
DBD
NVDA
...
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
a month ago - By: Regeneron Pharmaceuticals, Inc.
- Mentions:
REGN
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
a month ago - By: Zacks Investment Research
- Mentions:
REGN
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
2 months ago - By: Investor's Business Daily
- Mentions:
DNTH
ARGX
AZN
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
2 months ago - By: Zacks Investment Research
- Mentions:
REGN
LLY
NKTR
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
Please enable JavaScript to continue using this application.